References:

1. Nurtec ODT 75 mg UAE LPD USPI. Revision date May 2021.

2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 745-737:)10200(394;31.
3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 3/2, randomised, double-blind, placebo-controlled trial. Lancet. 60-51 :)10268(397;2020. doi:10.1016/S7-32544)20(6736-0140.

Dear Doctor,
Pfizer cordially invites you to attend a scientific meeting entitled:
“DISSOLVING THE LINE BETWEEN ACUTE & PREVENTIVE TREATMENT FOR MIGRAINES “
CME ACCREDITED

12th October 2022 7:00 - 8:45 PM Shangri-La Qaryat Al Beri -

Abu Dhabi
AGENDA
SPEAKERS
Time Topic SPEAKER
Dr. Naji Riachi Dr. Eman Ghazi
7:00 – 7:45 PMConsultant
Migraine Management
Neurology – and Dr. Mostafa
Consultant Shakra
Neurology -
unmet needs
Sheikh Shakhbout Medical City, Mediclinic Airport Road
7:45 – 8:00 PMAbu Dhabi
Q&A Hospital.
All

8:00 – 8:45 PM
AGENDA Dissolving the line between ACUTE & PREVENTIVE
treatment for Migraines – Role of Rimegepant
Dr. Mohamed Saidam

Time
8:45 – 9:00 PM
Topic
Q&A
SPEAKER
All
7:00–7:45 PM Migraine Diagnosis, Management, Dr. Eman Ghazi
and unmet needs
7:45 – 8:30 PM Many Migraines need one simple Dr. Naji Riachi
solution – Role of Rimegepant

8:30 – 8:45 PM Q&A All

LOOKING FORWARD TO MEETING YOU

This Webinar invitation is intended only to the recipient and should not be forwarded to any other third party.

For further information and to get the

Abbreviated Prescribing Information
please scan the QR code